VEGFR | 陶素生化

VEGFR

T0093	Sorafenib tosylate	Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-3/B-Raf).
T0093L	Sorafenib	Sorafenib is a potent multikinase inhibitor (IC50s: 6/20/22 nM for Raf-1/VEGFR-4/B-Raf).
T0097L	Pazopanib	Pazopanib, a small molecule inhibitor, inhibits multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits VEGFR-1, -2 and -3, c-kit a
T0129	Sanguinarine chloride	Sanguinarine chloride, a benzophenanthridine alkaloid, stimulates apoptosis by activating the production of reactive oxygen species (ROS).
T0342	Carvedilol phosphate	Carvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimeti
T0374	Sunitinib Malate	Sunitinib is an indolinone-based tyrosine kinase inhibitor. It blocks the tyrosine kinase activities of VEGFR2, PDGFRβ (IC50: 80/2 nM), and c-kit.
T0374L	Sunitinib	Sunitinib, a multi-targeted RTK inhibitor, is targeting PDGFRβ and VEGFR2 (Flk-1) with IC50 of 2 nM and 80 nM and also inhibits c-Kit.
T0447	Carvedilol	Carvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimeti
T0520	Lenvatinib	Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
T1452	Axitinib	Axitinib is an orally bioavailable tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.7, 1.6 nM for VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ, respectively.
T1656	Vandetanib	Vandetanib is a potent inhibitor of VEGFR2 (IC50: 40 nM). It also inhibits VEGFR3 and EGFR.
T1738	Taxifolin	Taxifolin is a flavonoid in many plants such as Taxus chinensis, Siberian larch, Cedrus deodara and so on.
T1754	ZM 306416	ZM 306416, a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).
T1777	Nintedanib	Nintedanib is an inhibitor of the receptor tyrosine kinases VEGFR/FGFR/PDGFR (IC50s: 13-34/37-610/59/65 nM for VEGFR1-3, FGFR1-4, and PDGFRα/β, respectively).
T1792	Regorafenib	Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
T1797	Cabozantinib Malate	Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activ
T1836	AZD2932	AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3, and c-Kit.
T1837	BX912	BX-912 is a specific inhibitor of 3-Phosphoinositide-dependent Kinase-1 (PDK1, IC50: 12 nM). The selectivity of BX-912 is more 10 fold than C-Kit, EGFR, PKA, PKC etc.
T1895	SKLB 610	SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2, and PDGFR at a rate of 97%, 65%, and 55%, respectively, at the concentration
T1936	Alectinib	CH5424802 is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
T1948	AZD4547	AZD4547, a new-type specific FGFR inhibitor, targets for FGFR1/2/3 (IC50: 0.2/2.5/1.8 nM in cell-free assays).
T1985	WHI-P154	WHI-P154 is a potent JAK3 inhibitor.
T2054	Altiratinib	Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as co
T2056	UNC0064-12	UNC0064-12 is a patent compound in WO2013055780A1, multikinase inhibitor and has a -NH2 terminal linker for further synthesis.
T2064	Semaxinib	Semaxanib (SU5416) is a potent and selective VEGFR2 inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR than PDGFRβ, lack of activity against InsR, EGFR, and FGFR. Semaxa
T2288	Motesanib	Motesanib is an orally bioavailable receptor tyrosine kinase inhibitor with potential antineoplastic activity. AMG 706 selectively targets and inhibits vascular endothelial growth
T2288L	Motesanib Diphosphate	Motesanib Diphosphate is the orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity.
T2358	ENMD2076	ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.
T2361	LY2874455	LY2874455 has been used in trials studying the treatment of Advanced Cancer.
T2372	Ponatinib	Ponatinib is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
T2415	PP121	PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , also inhibits DNA-P
T2419	BMS794833	BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
T2421	SKLB1002	SKLB1002 is a potent and ATP-competitive VEGFR2 inhibitor with IC50 of 32 nM.
T2446	KI8751	KI8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
T2456	Tivozanib	Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.
T2496	(Z)-Semaxinib	Semaxanib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for FGFR, InsR, and EGFR. Sem
T2500	Cediranib	Cediranib (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (IC50: 5 nM/≤3 nM), similar a
T2514	Linifanib	Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib
T2576	Brivanib Alaninate	Brivanib Alaninate is the alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to an
T2586	Cabozantinib	Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
T2624	OSI 930	OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesi
T2642	PD173074	PD173074 is an effective FGFR1 inhibitor (IC50: 25 nM) and also inhibits VEGFR2 (IC50: 100-200 nM) in cell-free assays. The selectivity is higher ~1000-fold for FGFR1 than PDGFR an
T2656	Fruquintinib	Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities
T2906	Tanshinone IIA	Tanshinone IIA(Tanshinone B) is the diterpene quinone in Danshen, which is utilized in the treatment of cardiovascular and inflammatory.
T3113	Foretinib	Foretinib is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
T3463	NVP-ACC789	ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.
T3476	JI101	JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephri
T3560	Desmethylanethol trithione	ADT-OH is a derivative of anethole dithiolethione (ADT) and synthetic hydrogen sulfide (H2S) donor. In the in vitro glucose-oxygen deprivation (OGD) model, ADT-OH markedly attenuat
T3566	SU 5205	SU 5205 is a VEGFR2 inhibitor.
T3570	NSC 86429	SU-4312, also known as DMBI, is a potent and selective inhibitor of VEGFR and PDGFR tyrosine kinases (IC50 values are 0.8 and 19.4 μM respectively). SU4312 unexpectedly protects a
T3599	BFH772	BFH772, a structure analogue of BAW2881, is a potent and selective VEGF inhibitor. BFH772 is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM. BFH772 inhibits
T3641	BAW2881	BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit chronic and acute skin inflammati
T3691	SAR131675	SAR131675 is an effective and specific VEGFR-3 inhibitor. It inhibited VEGFR-3 tyrosine kinase activity (IC50: 20 nmol/L) and VEGFR-3 autophosphorylation (IC50: 45 nmol/L) in HEK c
T3980	Su1498	SU 1498 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 (VEGFR2, aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and
T4026	VEGFR2 Kinase Inhibitor I	VEGFR2 Kinase Inhibitor I is a potent, cell-permeable inhibitor of the VEGFR2 kinase.
T4053	AST 487	AST 487 is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
T4075	Sulfatinib	Sulfatinib may be a potent drug for cancer. It inhibits KDR and FGFR1 enzymatic activity. It also is a hERG inhibitor.
T4209	TAK-659 hydrochloride	TAK-659 is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most other kinases, but potent toward both SYK and
T4288	hVEGF-IN-1	hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.
T4425	JK-P3	JK-P3 is a pyrazole-based inhibitor of VEGFR-2 (IC50: 7.8 μM). JK-P3 inhibits FGFR 1/3 kinase activity in vitro, but has no effect on FGFR signaling in cell-based assays. The comp
T4554	AG 1406	AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.
T6003	GSK1904529A	GSK1904529A is a specific inhibitor of IGF-1R (IC50=27 nM) and IR(IC50=25 nM) .
T6028	PF477736	PF-477736 is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
T6036	Brivanib	Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.
T6057	URMC099	URMC-099 is an orally bioavailable, brain penetrant MLK inhibitor (IC50: 19/42/14/150 nM, for MLK1/MLK2/MLK3/DLK), and also inhibits LRRK2 activity (IC50: 11 nM).
T6091	CP673451	CP-673451 is a specific inhibitor of PDGFRα/β (IC50: 10/1 nM) with antiangiogenic and antitumor activity and the selectivity is higher 450-fold than other angiogenic receptors.
T6128	PHA665752	PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
T6137	KRN633	KRN-633 is an effective VEGFR inhibitor. The IC50s of KRN-633 for VEGFR1, VEGFR2, and VEGFR3 is 170, 160 and 125 nM, respectively.
T6154	SU11274	SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.
T6166	Telatinib	Telatinib is an effective inhibitor of VEGFR2/3, c-Kit, and PDGFRα. The IC50s of Telatinib forVEGFR2/3, c-Kit and PDGFRα are 6 nM/4 nM, 1 nM, and 15 nM, respectively.
T6184	Orantinib	TSU-68, a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R,
T6193	Dovitinib Dilactic Acid	Dovitinib Dilactic acid (TKI258 Dilactic acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM,
T6289	Dovitinib	Dovitinib (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs (IC5
T6351	MGCD-265 analog	MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 1
T6458	CYC116	CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM, is less potent to VEGFR2 (Ki of 44 nM), with 50-fold greater potency than CDKs, not active against PKA, Akt/PKB
T6479	Dovitinib Lactate	Dovitinib (TKI258) Lactate is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (F
T6517	Golvatinib	Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases
T6720	Vatalanib 2HCl	Vatalanib (PTK787) (IC50=37 nM) is an inhibitor of VEGFR2/KDR. It exhibits less effective against VEGFR1/Flt-1 and 18-fold against VEGFR3/Flt-4.
T6730	WAY600	WAY-600 is a potent, ATP-competitive and selective inhibitor of mTOR with IC50 of 9 nM; blocks mTORC1/P-S6K(T389) and mTORC2/P-AKT(S473) but not P-AKT(T308); selective for mTOR tha
T6882	LY3009120	LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.
T6930	Pazopanib HCl	Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 14
T6996	SU5402	SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.
T4315	Ki20227	Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respecti
T4318	ACTB1003	ACTB-1003 is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
T5S1632	8-O-Acetylshanzhiside methyl ester	8-O-Acetylshanzhiside methylester has potential against cerebral ischemic injury, and its protective effect on oxygen-glucose deprivation-induced injury might be due to the suppres
T5001	Nintedanib Ethanesulfonate Salt	BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
T5153	Apatinib mesylate	Apatinib is an orally bioavailable and specific VEGFR2 inhibitor (IC50: 1 nM). In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.
T5164	Cabozantinib hydrochloride (849217-68-1(free base))	Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).
T9904	Bevacizumab	Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a hum
T9928	Ranibizumab	Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A
T5349	SCR-1481B1	SCR-1481B1 has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
T5466	Tyrosine kinase-IN-1	Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor（KDR, Flt-1, FGFR1 and PDGFRα with IC50s of 4nM, 20nM, 4nM, 2 nM ,respectively）
T5475	ZD-4190	ZD-4190 is a inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cance
T7203	Oglufanide	Oglufanide is a naturally occurring thymic immunomodulator,and inhibits vascular endothelial growth factor (VEGF).
T7493	AG-13958	AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration.
TQ0317	R1530	R1530 is a multikinase inhibitor with antineoplastic and antiangiogenesis activities.
TQ0321	BIBF 1202	BIBF 1202 is a VEGFR2 kinase inhibitor (IC50: 62 nM).
TQ0080	SU14813 maleate	SU14813 maleate is an inhibitor of multi-targeted receptor tyrosine kinases (IC50s: 2, 50, 4, 15 nM for VEGFR1, VEGFR2, PDGFRβ, and KIT).
TQ0021	Ningetinib	Ningetinib (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
TQ0041	Ningetinib Tosylate	Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
TQ0166	Tesevatinib	Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4).
T5171	Treprostinil Sodium	Treprostinil is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).
T4349	Sitravatinib	Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
T6199	Ribociclib	LEE011 is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
T7945	SU14813	SU14813 is a multi-receptor tyrosine kinase inhibitor with potent antiangiogenesis and antitumor activity (IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT).
T8402	Regorafenib Hydrochloride	Regorafenib Hydrochloride is a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
TN1042	Chebulic acid	Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity,which breaks the cross-links of proteins induced by advanced glyc
TN1095	Ginsenoside Rk2	Ginsenoside Rk1 has anti-tumor, and anti-platelet aggregation activities.
TN1557	Decursinol angelate	Decursinol angelate has anti-tumor, anti-inflammatory, anti-oxidant, and hepatoprotective activities, it inhibits VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling
TN1567	Delphinidin chloride	Delphinidin chloride is a dietary antioxidant.
TN1853	Lariciresinol	Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for th
TN1126	Sakuranetin	Sakuranetin, a flavanone phytoalexin from ultraviolet-irradiated rice leaves, it has antifungal, antimutagenic, anti-inflammatory and antioxidant effects
TN1867	Licoricidin	Licoricidin, is a potent anti-metastatic agent, which can markedly inhibit the metastatic and invasive capacity of malignant prostate cancer cells.
T8326	BMS-2	BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
T8491	Vorolanib	Vorolanib is an orally active VEGFR/PDGFR dual inhibitor.
T14943	CGP60474	CGP60474 is an inhibitor of VEGFR-2 (IC50: 84 nM) and an ATP-competitive inhibitor of PKC.
T10870L	CP-547632	CP-547632 is a well-tolerated, orally-bioavailable inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50s: 11 nM and 9 nM) with antitumor efficacy.
T15185	Lucitanib	Lucitanib (E-3810) is a novel dual VEGFR and FGFR inhibitor. It potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 (IC50s: 7 nM, 25 nM, 10 nM, 17.5 nM, and 8
T13039	Sunitinib D10	Sunitinib D10 is a deuterium labeled Sunitinib. Sunitinib is a inhibitor of multi-targeted receptor tyrosine kinase(IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively).
T13108	TAS-115	TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).
T13156L	TG 100572 Hydrochloride	TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM fo
T13156	TG 100572	TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGF
T13157L	TG 100801 Hydrochloride	TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1,
T13157	TG 100801	TG 100801 is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1
T10123	KDR-in-4	KDR-in-4 is an effective inhibitor of kinase insert domain-containing receptor (KDR/VEGFR2) (IC50: 7 nM).
T13407	ZK756326 dihydrochloride	ZK756326 dihydrochloride is a agonist of nonpeptide chemokine receptor for the CC chemokine receptor CCR8.
T13178	Toceranib	Toceranib phosphate is an orally active inhibitor of tyrosine kinase (RTK) receptor, and it potently inhibits PDGFR, VEGFR, and Kit(with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR
T8496	MAZ51	MAZ51 is a VEGFR-3 (Flt-4) tyrosine kinase inhibitor.
T16975	TAK-593	TAK-593 is an effective VEGFR and PDGFR family inhibitor (IC50s: 3.2, 0.95, 1.1, 4.3, and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα, and PDFGRβ, respectively).
T17219	Vatalanib free base	Vatalanib is a VEGFR2/KDR inhibitor (IC50: 37 nM).
T2S0501	Ilexgenin A	Ilexgenin A is a novel pentacyclic triterpenoid, is a compound extracted from leaves of Ilex hainanensis Merr
T5S1467	Cucurbitacin E	Cucurbitacin E is a natural product isolated from the climbing stem of Cucumic melo L. It significantly suppresses the activity of the cyclin B1/CDC2 complex.Cucurbitacin E has pre
TN3587	Capillarisin	Capillarisin is a novel blocker of STAT3 activation and thus may have a potential in negative regulation of growth, metastasis, and chemoresistance of tumor cells, it inhibits canc
TMA2474	Delta-Tocotrienol	Delta-tocotrienol is a potential angiogenic inhibitor, it (2.5-5 microM) can significantly suppress human colorectal adenocarcinoma cells (DLD-1-CM) -induced tube formation, migrat
TMA1743	Ergosterol peroxide	Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Foxo3a activity by inh
TN4603	Myricanol	Myricanol can elicit growth inhibitory and cytotoxic effects on lung cancer cells, it can significantly decelerate tumor growth in vivo by inducing apoptosis.
TN4748	Penduletin	Penduletin has anti-inflammatory,anti-tumor cells, and anti-bacterical activities,it inhibits growth of the Gram-negative pathogen neisseria gonorrhoeae. Penduletin has strong acti
TN4913	Riddelline	Riddelline is a potent genotoxic agent in vitro and induces significant elevations in unscheduled DNA synthesis and S-phase synthesis in rat liver.
TN5050	Sprengerinin C	Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can strongly suppress tum
TN5100	Taspine	Taspine shows antitumor activity by modulating the EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo, it can inhibit growth and induce apoptosis of HUVEC in a dose-depe
TN5246	Voacangine	Voacangine is a novel transient receptor potential vanilloid type 1 (TRPV1) antagonist, it shows mod. cytotoxic activity, also some CNS, brachycardial and hypotensive action.Voacan
TN5250	Vomifoliol	Vomifoliol is most likely the immediate precursor of dehydrovomifoliol, because of the organism converted abscisic acid (ABA), to dehydrovomifoliol as the major metabolise, and a c
T22432	SU5208	SU5208 is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).
T22431	SU5204	SU5204, an analogue of SU5025, pharmacologically inhibits VEGFR2(IC50s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2)
T2056L	UNC0064-12 hydrochloride (1430089-64-7(free base))	UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1
T1792L	Regorafenib monohydrate	Regorafenib Monohydrate is a novel oral multikinase inhibitor with IC50 values of 13, 4.2, 46, 22, 7, 1.5, 2.5, 28, 19 nM for VEGFR1, murine VEGFR2, murine VEGFR3, PDGFR-β, KIT, R
T11520	GW806742X	GW806742X is an inhibitor of Mixed Lineage Kinase Domain-Like protein (MLKL) which binds the MLKL pseudokinase domain (Kd: 9.3 μM) with anti-necroptosis activity. GW806742X has a
TJS0339	Coumarin-3-carboxylic acid	The combination of Valproic acid with coumarin-3-carboxylic acid suppresses the proliferation and migration of lung cancer cells via EGFR/VEGFR2/c-Met-Akt-NF-κB signaling pathways
T8541	Lenvatinib mesylate	Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
T7611	ODM-203	ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity
TQ0059	Ilorasertib	Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppresses RET tyrosine kin
TQ0059	Ilorasertib	Ilorasertib (ABT-348) is an ATP-competitive multitargeted kinase inhibitor, which inhibits Aurora A/Aurora B/Aurora C (IC50s: 120 nM/7 nM/1 nM). It also suppresses RET tyrosine kin
T12145L	N-Desethylsunitinib hydrochloride	N-Desethylsunitinib hydrochloride is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFRβ, and KIT inhibitor.
T17280	(Z)-Guggulsterone	(Z)-Guggulsterone inhibits the growth of human prostate cancer cells by causing apoptosis. Z-guggulsterone inhibits angiogenesis by suppressing the VEGF–VEGF-R2–Akt signaling a